K. Rene Ward
Associate Director, Public Relations and Internal Communications
3902 Gene Field Road
St. Joseph, Missouri 64506
Keeping beef quality in mind during a dairy cow’s lifetime can increase her value
Should dairy producers consider themselves beef producers? According to Dr. Linda Tikofsky, Professional Services Veterinarian with Boehringer Ingelheim Vetmedica, Inc., the answer is a resounding “yes!”
“At this point, most dairy producers do not think of themselves as beef producers,” says Dr. Tikofsky. “Dairymen know they ship cull cows for beef, but I don’t think they recognize the impact some of their dairy practices have on beef quality in the long run.”
Many common practices, while effective for milk quality and production, can cause a reduction in beef quality once a cull cow arrives at a packinghouse. The long-term effects of some of these practices cause the dairy cull cows to be flagged for further examination at the packinghouse, leading to fines and loss in value for dairy producers.
“If we’re marketing them later, after we’ve treated them a number of times or after they’ve lost a significant amount of body condition, the cows are much more likely to be flagged for additional review and receive more scrutiny,” says Dr. Tikofsky.
She recommends the following steps to help preserve beef quality throughout a dairy cow’s life:
“We know that prevention works,” says Dr. Tikofsky, “we just need to continue to implement it.”
For additional information on handling guidelines and vaccine administration protocols, visit www.BQA.org. For additional details about Prevention Works, contact your local veterinarian or Boehringer Ingelheim Vetmedica, Inc. representative, or visit www.BIVIPreventionWorks.com.
Prevention Works does not imply prevention label claims for use of a vaccine/vaccines.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO) is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT, and a member of the Boehringer Ingelheim group of companies.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to be socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability, are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area of Prescription Medicines corresponds to 23.5 percent of its net sales.